Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 12/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15949367 | 0.93 | UTS2R (0.39) | UTS2RMDM2BCL2PPARAPPARG | |
| SCHEMBL958964 | 0.89 | KMT2A (0.36) | L3MBTL1MEN1KMT2A | |
| SCHEMBL15163671 | 0.88 | UTS2R (0.38) | UTS2RMDM2BCL2PPARAPPARG | |
| SCHEMBL958625 | 0.88 | UTS2R (0.38) | UTS2RMDM2BCL2PPARAPPARG | |
| SCHEMBL15163670 | 0.88 | UTS2R (0.38) | UTS2RMDM2BCL2PPARAPPARG | |
| SCHEMBL735527 | 0.80 | SMN1; SMN2 (0.34) | L3MBTL1MEN1KMT2A | |
| SCHEMBL116410 | 0.80 | SMN1; SMN2 (0.34) | L3MBTL1MEN1KMT2A | |
| SCHEMBL956652 | 0.78 | SMN1; SMN2 (0.34) | L3MBTL1MEN1KMT2A | |
| SCHEMBL1869071 | 0.78 | UTS2R (0.46) | UTS2RL3MBTL1MEN1KMT2A | |
| SCHEMBL1869067 | 0.78 | UTS2R (0.46) | UTS2RL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324017-B1 | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2014-12-31 | — | — | EP | disclosed |
| EP-2324017-B1 | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-8846668-B2 | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846668-B2 | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846668-B2 | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2183228-B1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8637505-B2 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-8637505-B2 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-8637505-B2 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-8575156-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110312950-A1 | CYCLIC INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312950-A1 | CYCLIC INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| EP-2393807-A1 | CYCLIC INHIBITORS OF 11 -HYDROXYSTEROID DEHYDROGENASE 1 | Boehringer Ingelheim International GmbH (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals ,Inc. | 2011-01-20 | — | — | US | disclosed |
| WO-2010089303-A1 | CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010089303-A1 | CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | WO | disclosed |
| EP-2183228-A1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010010157-A2 | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312950-A1 | CYCLIC INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD11B2 | UTS2R 3988/4885MDM2 4530/4885L3MBTL1 3592/4885 |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | UTS2R 4397/4885MDM2 4642/4885L3MBTL1 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.